Previous 10 | Next 10 |
2024-02-02 08:32:47 ET CCSC Technology International Holdings ( CCTG ) +39% . Minim ( MINM ) +38% . TruGolf Holdings ( TRUG ) +36% . Kopin ( KOPN ) +21% . Meta Platforms ( META ) +17% Q4 earnings call rele...
- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code - - Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile - Revance Therapeutics, Inc. (RVNC) today announ...
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6 th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in ...
2024-01-29 09:00:19 ET NASDAQ: RVNC 3.5% More on Revance Therapeutics Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Revance Therapeutics expects to achieve positive...
2024-01-12 16:40:04 ET Gainers: Outset Medical ( OM ) +11% . Kandi Technologies Group ( KNDI ) +7% . Dyne Therapeutics ( DYN ) +5% . Revance Therapeutics ( RVNC ) +4% . NovoCure Limited ( NVCR ) +3% . Losers: Gritstone...
2024-01-11 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-10 16:46:06 ET More on AbbVie AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen Investor's Dilemma: AbbVie Stock Amidst U.S. Election And Humira Decline AbbVie announces EU availa...
2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...
2024-01-08 11:47:12 ET More on Revance Therapeutics Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Public Citizen petitions FDA for stricter warnings against Botox, similar drug...
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 m...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...